Depemokimab was shown to reduce exacerbations in patients with severe asthma. The proportions of adverse events of ...

(Bloomberg) -- GSK Plc and Flagship Pioneering Inc. entered ... Inc. in 2023 for about $2 billion to secure a promising cough ...

GSK has taken another step towards rebuilding ... in late-stage development as a chronic cough therapy. The big pharma needs to boost its pipeline as it is facing patent expiry in 2027 for HIV ...

GSK recorded positive topline data in a late stage trial of its respiratory syncytial virus vaccine combined with a shingles vaccine in treating adults 50 years and older.

GlaxoSmithKline Pharmaceuticals Ltd. engages in the business of manufacturing, distributing and trading in pharmaceuticals. The company's product portfolio includes prescription medicines and ...

GSK’s depemokimab, a new ultra-long-acting biologic, showed a 54% reduction in severe asthma exacerbations in the SWIFT-1 and ...

Therapeutic area expertise motivated GSK to acquire Bellus Health and develop a new medicine for patients with refractory chronic cough ... agreements with Hansoh Pharma for novel ADCs in oncology.

Japan’s Taisho Pharmaceutical ... and over-the-counter medicine manufacturer – the largest in Japan and known for brands like Lipovitan energy drinks and Pabron cough/cold range – reckons ...

GSK plc (LSE/NYSE: GSK) today announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, reactogenicity and safety of AREXVY (Respiratory ...

New Delhi: Following the deaths of at least 141 children worldwide connected to cough ... Pharma firms manufacturing GlaxoSmithKline's T-Minic Oral Drops, Glenmark's Ascoril Flu Syrup, and IPCA ...

The World Health Organization and partners on Friday set up a scheme to help bring mpox vaccines, tests and treatments to the ...